App-Quantinova.ai

Evaluating patient out-of-pocket (OOP) expenses using real world utilization data of botulinum toxins

L. Turner-Stokes - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Botulinum toxin A

Evaluating the use of Parkinson’s Kinetigraphs in Patients with Parkinson’s Disease and Frailty

B. Mohamed - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Evaluation of the effect of Bilateral Subthalamic Nucleus Deep Brain Stimulation on fatigue in Parkinson’s disease

C. Lazcano Ocampo - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Exploring the pathophysiology of acquired dystonia by the use of high frequency somatosensory stimulation

A. Latorre - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Feasibility and Acceptability of Lee Silverman Voice Treatment for patients with hereditary ataxia

A.N. Lowit - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Friedreich ataxia

N/A

Fixed-life or rechargeable battery for deep brain stimulation: A prospective long-term study of patient’s preferences

L. Furlanetti - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Genome-wide association studies of progression in Parkinson’s disease

M. Tan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Home Based Care: A care pathway innovation for Parkinson’s disease

E. Edwards - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Identification and Documentation of Delirium in Parkinson’s Disease

R. Cullinan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Identifying neural signatures of Parkinson’s disease that predict decline in gait and postural control

H. Sigurdsson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Identifying Neuropsychiatric Profiles in Parkinson’s disease, Dementia with Lewy Bodies and Alzheimer’s disease

D. Smith - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lewy body dementia

N/A

Improving automaticity of walking in Parkinson’s disease: Levodopa or Donepezil?

S. Stuart - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Donepezil

Improving estimation of Parkinson’s disease risk – enhancing the PREDICT-PD algorithm

J. Bestwick - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

In vivo markers of anxiety in drug-naïve Parkinson’s disease

H. Wilson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington’s disease: the prospective HD-CSF study

F. Rodrigues - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Loss‐of‐function mutations in NR4A2 cause dopa‐responsive dystonia-parkinsonism

T. Wirth - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Management of neuropsychiatric symptoms in Parkinson’s disease (PD) at the front door

M.A Farooqi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Mental Health Matters Too – Integration of physical and mental health in a multidisciplinary Parkinson’s Clinic

C. Taylor - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Microstructural changes in GBA mutation carriers with depression

H. Wilson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Movement disorders associated with expansions and intermediate repeats in the C9orf72 gene

C. Estevez-Fraga - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Filters

45280 Abstracts